NOTICE OF UPGRADE
Our websites will be unavailable between the hours of AEST 4AM September 17, 2022 and AEST 11PM on date September 18, 2022
SEARCH LISTED COMPANY
Any AUS or NZ company
SEARCH PRIVATE COMPANY
SEARCH FUNDS
Find any Australian or New Zealand company or fund (dead or alive) by using SEARCH above or go directly to the site:
|
|
13 July 2025
| Name: | OPYL LIMITED (OPL) | ||||||||||||
| ISIN: | AU0000070856 | ||||||||||||
| Date of Listing: | 07 March 1996 | ||||||||||||
| Former Names: |
|
Stock Exchange Status: (updated daily)
This entity is currently listed and quoted on the Australian Securities Exchange.Legal Status: (updated monthly)
ACN: 063 144 865ABN: 71 063 144 865
Registration Date: 17 January 1994
Capital Gains Tax (CGT) Status: (updated at least quarterly)
To crystallise a capital gain or capital loss on your securities in this entity, you are able to sell your securities on-market in the normal manner. If you determine that the market in your securities is illiquid and you still wish to crystallise a capital gain or loss, kindly contact deListed at admin@delisted.com.au for suggestions as to how you might proceed.
Updates, corrections, disagreements please email to admin@delisted.com.au
Further information: deListed and InvestoGain are operated by Investogain Pty Limited which is licensed by ASIC as an Australian Financial Services Licensee (AFSL 334036). deListed acquires only securities that it deems to be of little or no value, in circumstances where the holder is unable to sell their securities on-market in the normal manner. This service has been provided online via the company’s website www.delisted.com.au since 2004.
Getting advice: Information provided in this section is of a general nature and applicable only to Australian tax residents who hold their investments on capital account (ie for long-term investment purposes). It has been prepared without taking into account your financial needs or tax situation. Before acting on the information, deListed suggests that you consider whether it is appropriate for your circumstances and recommends that you seek independent legal, financial, or taxation advice.
Disclaimer: The information provided above is to the best of our knowledge accurate as of today. But you should bear in mind that it is of a general nature and does not constitute financial or tax advice. Investogain Pty Limited accepts no liability for any loss arising from reliance on this information, including reliance on information that is no longer current.
| FROM | TO | |
| OPYL LIMITED | 11/12/2019 | |
| SHAREROOT LTD | 21/12/2015 | 11/12/2019 |
| MONTO MINERALS LTD | 21/02/2003 | 21/12/2015 |
| MONTO MINERALS NL | 21/02/2003 |
Automic Group
Level 5, 126 Philip Street Sydney NSW 2000
GPO Box 5193 Sydney NSW 2001
Tel : 1300 288 664 or +61 2 9698 5414
Fax : +61 2 8583 3040
RegistryWebsite RegistryEmail
Expand this box to read and print
The suspension of trading in the securities of Opyl Limited will be lifted immediately following the release by OPL of an announcement regarding a non-binding offer to acquire the Opin business from OPL. | 22/03/2024 |
The Company has received a non-binding offer to acquire its patient candidate recruitment business, Opin, from Trial Screen Pty Ltd, an entity controlled by Dr Hugo Stephenson. The non-binding offer proposes a divestment of Opin for A$1 and 20% of the equity in Trial Screen. The divestment is expected to be completed by 30 April 2024. The divestment of Opin will be subject to shareholder approval under ASX Listing Rule 11.2. As part of the sale, Opyl will transfer all Opin related intellectual property, key employees, key clients, and brand assets pertaining to the Opin business. The divestment will significantly improve Opyl's monthly cashflow and enable greater focus on driving growth for TrialKey, noting Opin was responsible for approximately $700K ($60k per month) in net cash outflows per year on a standalone basis. The divestment will enable the Company to redeploy capital and resources towards its AI solution TrialKey advancing its ongoing commercialisation. | 22/03/2024 |
The Company has received a non-binding offer to acquire its patient candidate recruitment business, Opin, from Trial Screen Pty Ltd, an entity controlled by Dr Hugo Stephenson. The non-binding offer proposes a divestment of Opin for A$1 and 20% of the equity in Trial Screen. The divestment is expected to be completed by 30 April 2024. The divestment of Opin will be subject to shareholder approval under ASX Listing Rule 11.2. As part of the sale, Opyl will transfer all Opin related intellectual property, key employees, key clients, and brand assets pertaining to the Opin business. The divestment will significantly improve Opyl's monthly cashflow and enable greater focus on driving growth for TrialKey, noting Opin was responsible for approximately $700K ($60k per month) in net cash outflows per year on a standalone basis. The divestment will enable the Company to redeploy capital and resources towards its AI solution TrialKey advancing its ongoing commercialisation. | 22/03/2024 |
The securities of Opyl Limited will be suspended from quotation immediately under Listing Rule 17.2, at the request of OPL, pending the release of an announcement regarding a non-binding offer to acquire the Opin business from OPL. | 22/03/2024 |
The suspension of trading in the securities of Opyl Limited will be lifted immediately following the release of an announcement by OPL regarding an entitlement offer. | 12/12/2023 |
The company releases a Cleansing Notice regarding the entitlement offer. | 12/12/2023 |
The company releases a notice of proposed issue of securities. | 12/12/2023 |
Opyl has successfully completed a $576,000 placement at an offer price of $0.03 per share from professional and sophisticated investors. A 2 for 5 non-renounceable rights issue offer at $0.03 per share is also being offered to eligible shareholders to raise up to $1.43m. Opyl has secured advanced commitments for $635,000 in a combination of rights acceptances in advance and shortfall commitments prior to the Entitlement Offering opening date. Proceeds from both the placement and rights issue will be used to progress the commercialisation of Opyl's recently launched predictive analytics and clinical trial insights platform, TrialKey. | 12/12/2023 |
The securities of Opyl Limited will be suspended from quotation immediately under Listing Rule 17.2, at the request of OPL, pending the release of an announcement regarding an entitlement offer. | 12/12/2023 |
The suspension of trading in the securities of Opyl Limited will be lifted immediately following the release by OPL of an announcement regarding a capital raise. | 23/12/2022 |
The company releases a Rights Issue Offer Booklet. | 23/12/2022 |
The company announces a non-renounceable rights issue, to raise up to $480,390. The funds raised from the placement and rights issue will be applied to: accelerating the conversion of the sales pipeline, development and release of additional functionality on Opin that provides for greater automation connecting patients to trial sites, supporting scale and additional income stream, expansion of Opin into key APAC markets (NZ, Korea and Taiwan) and first entry into US markets, ongoing product development and enhancement, working capital. | 23/12/2022 |
The company releases a letter to its ineligible shareholders regarding the rights issue. | 23/12/2022 |
The company releases a cleansing notice in relation to its nonrenounceable rights issue offer to eligible shareholders. | 23/12/2022 |
The company makes a clarification on its announcement. The company wants to correct this statement: "The Placement Shares are intended to be issued under the Company's current capacity pursuant to ASX Listing Rule 7.1(8,157,808 Shares) and 7.1A (5,438,538 Shares)." This should state: The Placement Shares are intended to be issued under the Company's current, capacity pursuant to ASX Listing Rule 7.1(8,157,808 Shares) and 7.1A (1,508,859 Shares). | 23/12/2022 |
The company releases a notice of proposed issue of securities. | 23/12/2022 |
Opyl has successfully received commitments from institutional and sophisticated investors for approximately $290,000 at $0.03 via a placement. A 1 for 4 non-renounceable rights issue offer at $0.03 per share is being offered to eligible shareholders to raise up to A$480,390. A top-up facility will be offered, under which eligible shareholders can apply to take up new shares in excess of their pro-rata entitlement. Proceeds from the raises will be used to extend Opin's market share in APAC, accelerate conversion of the sales pipeline, open new functionality in Opin, ongoing product development and enhancement and improve working capital. | 23/12/2022 |
The securities of Opyl Limited will be suspended from quotation immediately under Listing Rule 17.2, at the request of OPL, pending the release of an announcement regarding a capital raise | 23/12/2022 |
The suspension of trading in the securities of Opyl Limited will be lifted immediately following the release by OPL of an announcement regarding the Company's announcement dated 3 September 2020. | 07/09/2020 |
The company provides additional information in relation to its announcement on 3 September 2020. The cost of the product to date has been circa $800k. The software is now functional however the company will continue to further improve and refine the software with future upgrades and expansion of features, which is anticipated to cost up to another $500K in development. The company will continue to develop its marketing, sales and ongoing customer service support expenditure forecast models as well as revenue models and provides shareholders and the market with updates. The company is currently finalising its R&D application for the 2020 financial year. | 07/09/2020 |
The securities of Opyl Limited will be suspended from quotation immediately under Listing Rule 17.2, at the request of OPL, pending the release of an announcement. | 04/09/2020 |
In reference to the two new contracts, individually, these do not represent a material event as they will not increase the company's forecast revenue by greater than 10% for the year ended 30 June 2020. The intention of the company's announcement on 20 May 2020 is to provide shareholders regular and ongoing overview in respect of its progress. Additional information in relation to these contracts have been provided. | 25/05/2020 |
The suspension of trading in the securities of Opyl Limited ("˜OPL') will be lifted from the commencement of trading on Tuesday, 26 May 2020, following the release by OPL of an announcement regarding the two new contracts announced on Wednesday 20 May 2020. | 25/05/2020 |
The securities of Opyl Limited will be suspended from quotation from the commencement of trading on Friday 22 May 2020 under Listing Rule 17.2, at the request of OPL, pending the release of an announcement regarding the two new contracts announced on Wednesday 20 May 2020. | 22/05/2020 |
name changed from ShareRoot Ltd | 11/12/2019 |
The suspension of trading in the securities of Opyl Limited will be lifted immediately following the release by OPL of an announcement regarding a non-binding offer to acquire the Opin business from OPL. | 22/03/2024 |
The Company has received a non-binding offer to acquire its patient candidate recruitment business, Opin, from Trial Screen Pty Ltd, an entity controlled by Dr Hugo Stephenson. The non-binding offer proposes a divestment of Opin for A$1 and 20% of the equity in Trial Screen. The divestment is expected to be completed by 30 April 2024. The divestment of Opin will be subject to shareholder approval under ASX Listing Rule 11.2. As part of the sale, Opyl will transfer all Opin related intellectual property, key employees, key clients, and brand assets pertaining to the Opin business. The divestment will significantly improve Opyl's monthly cashflow and enable greater focus on driving growth for TrialKey, noting Opin was responsible for approximately $700K ($60k per month) in net cash outflows per year on a standalone basis. The divestment will enable the Company to redeploy capital and resources towards its AI solution TrialKey advancing its ongoing commercialisation. | 22/03/2024 |
The Company has received a non-binding offer to acquire its patient candidate recruitment business, Opin, from Trial Screen Pty Ltd, an entity controlled by Dr Hugo Stephenson. The non-binding offer proposes a divestment of Opin for A$1 and 20% of the equity in Trial Screen. The divestment is expected to be completed by 30 April 2024. The divestment of Opin will be subject to shareholder approval under ASX Listing Rule 11.2. As part of the sale, Opyl will transfer all Opin related intellectual property, key employees, key clients, and brand assets pertaining to the Opin business. The divestment will significantly improve Opyl's monthly cashflow and enable greater focus on driving growth for TrialKey, noting Opin was responsible for approximately $700K ($60k per month) in net cash outflows per year on a standalone basis. The divestment will enable the Company to redeploy capital and resources towards its AI solution TrialKey advancing its ongoing commercialisation. | 22/03/2024 |
The securities of Opyl Limited will be suspended from quotation immediately under Listing Rule 17.2, at the request of OPL, pending the release of an announcement regarding a non-binding offer to acquire the Opin business from OPL. | 22/03/2024 |
The suspension of trading in the securities of Opyl Limited will be lifted immediately following the release of an announcement by OPL regarding an entitlement offer. | 12/12/2023 |
The company releases a Cleansing Notice regarding the entitlement offer. | 12/12/2023 |
The company releases a notice of proposed issue of securities. | 12/12/2023 |
Opyl has successfully completed a $576,000 placement at an offer price of $0.03 per share from professional and sophisticated investors. A 2 for 5 non-renounceable rights issue offer at $0.03 per share is also being offered to eligible shareholders to raise up to $1.43m. Opyl has secured advanced commitments for $635,000 in a combination of rights acceptances in advance and shortfall commitments prior to the Entitlement Offering opening date. Proceeds from both the placement and rights issue will be used to progress the commercialisation of Opyl's recently launched predictive analytics and clinical trial insights platform, TrialKey. | 12/12/2023 |
The securities of Opyl Limited will be suspended from quotation immediately under Listing Rule 17.2, at the request of OPL, pending the release of an announcement regarding an entitlement offer. | 12/12/2023 |
The suspension of trading in the securities of Opyl Limited will be lifted immediately following the release by OPL of an announcement regarding a capital raise. | 23/12/2022 |
The company releases a Rights Issue Offer Booklet. | 23/12/2022 |
The company announces a non-renounceable rights issue, to raise up to $480,390. The funds raised from the placement and rights issue will be applied to: accelerating the conversion of the sales pipeline, development and release of additional functionality on Opin that provides for greater automation connecting patients to trial sites, supporting scale and additional income stream, expansion of Opin into key APAC markets (NZ, Korea and Taiwan) and first entry into US markets, ongoing product development and enhancement, working capital. | 23/12/2022 |
The company releases a letter to its ineligible shareholders regarding the rights issue. | 23/12/2022 |
The company releases a cleansing notice in relation to its nonrenounceable rights issue offer to eligible shareholders. | 23/12/2022 |
The company makes a clarification on its announcement. The company wants to correct this statement: "The Placement Shares are intended to be issued under the Company's current capacity pursuant to ASX Listing Rule 7.1(8,157,808 Shares) and 7.1A (5,438,538 Shares)." This should state: The Placement Shares are intended to be issued under the Company's current, capacity pursuant to ASX Listing Rule 7.1(8,157,808 Shares) and 7.1A (1,508,859 Shares). | 23/12/2022 |
The company releases a notice of proposed issue of securities. | 23/12/2022 |
Opyl has successfully received commitments from institutional and sophisticated investors for approximately $290,000 at $0.03 via a placement. A 1 for 4 non-renounceable rights issue offer at $0.03 per share is being offered to eligible shareholders to raise up to A$480,390. A top-up facility will be offered, under which eligible shareholders can apply to take up new shares in excess of their pro-rata entitlement. Proceeds from the raises will be used to extend Opin's market share in APAC, accelerate conversion of the sales pipeline, open new functionality in Opin, ongoing product development and enhancement and improve working capital. | 23/12/2022 |
The securities of Opyl Limited will be suspended from quotation immediately under Listing Rule 17.2, at the request of OPL, pending the release of an announcement regarding a capital raise | 23/12/2022 |
The suspension of trading in the securities of Opyl Limited will be lifted immediately following the release by OPL of an announcement regarding the Company's announcement dated 3 September 2020. | 07/09/2020 |
The company provides additional information in relation to its announcement on 3 September 2020. The cost of the product to date has been circa $800k. The software is now functional however the company will continue to further improve and refine the software with future upgrades and expansion of features, which is anticipated to cost up to another $500K in development. The company will continue to develop its marketing, sales and ongoing customer service support expenditure forecast models as well as revenue models and provides shareholders and the market with updates. The company is currently finalising its R&D application for the 2020 financial year. | 07/09/2020 |
The securities of Opyl Limited will be suspended from quotation immediately under Listing Rule 17.2, at the request of OPL, pending the release of an announcement. | 04/09/2020 |
In reference to the two new contracts, individually, these do not represent a material event as they will not increase the company's forecast revenue by greater than 10% for the year ended 30 June 2020. The intention of the company's announcement on 20 May 2020 is to provide shareholders regular and ongoing overview in respect of its progress. Additional information in relation to these contracts have been provided. | 25/05/2020 |
The suspension of trading in the securities of Opyl Limited ("˜OPL') will be lifted from the commencement of trading on Tuesday, 26 May 2020, following the release by OPL of an announcement regarding the two new contracts announced on Wednesday 20 May 2020. | 25/05/2020 |
The securities of Opyl Limited will be suspended from quotation from the commencement of trading on Friday 22 May 2020 under Listing Rule 17.2, at the request of OPL, pending the release of an announcement regarding the two new contracts announced on Wednesday 20 May 2020. | 22/05/2020 |
name changed from ShareRoot Ltd | 11/12/2019 |
Your browser may reflect a date of printing in American format.
Purchases Sales
| DATE | DIRECTOR | NUMBER | PRICE | AMOUNT |
|---|---|---|---|---|
| 28/03/2025 | Antanas Guoga | 3,059 | $0.028 | $86 |
| 25/03/2025 | Antanas Guoga | 1,500,000 | $0.027 | $40,301 |
| 11/12/2024 | Antanas Guoga | 1,500,000 | $0.030 | $45,000 |
| 29/07/2024 | Antanas Guoga | 1,000,000 | $0.030 | $30,100 |
| 12/06/2024 | Antanas Guoga | 1,108,216 | $0.027 | $29,368 |
| NAME | TITLE | DATE OF APPT |
|---|---|---|
| Saurabh Jain | Executive Chairman | 24/11/2023 |
| Misha McPherson | COO | 02/03/2016 |
| Antanas Guoga | Non Exec Director | 04/09/2023 |
| Damon Rasheed | Executive Director | 01/02/2019 |
| Jonathan Hart | Company Secretary | 05/09/2024 |
Date of first appointment, title may have changed.
| NAME | TITLE | DATE OF APPOINTMENT | DATE OF RESIGNATION |
|---|---|---|---|
| David Lilja | Company Secretary | 05/09/2024 | |
| Mark Simari | Non Exec Director | 04/09/2023 | 01/09/2024 |
| Mark Ziirsen | Non Exec Chairman | 21/09/2020 | 30/04/2024 |
| Megan Robertson | Non Exec Director | 05/05/2021 | 04/09/2023 |
| Michelle Gallaher | CEO | 14/03/2019 | 05/07/2023 |
| Julian Chick | Chairman | 06/05/2019 | 14/02/2023 |
| Marat Basyrov | Non Exec Director | 01/03/2019 | 18/11/2021 |
| Andrew Bursill | CFO | 12/01/2016 | 24/05/2019 |
| Harvey Kaplan | Non Exec Director | 01/02/2019 | 06/05/2019 |
| Noah Abelson-Gertler | Executive Director | 12/01/2016 | 01/03/2019 |
| Lee Rodne | Non Exec Chairman | 26/04/2017 | 01/02/2019 |
| Peter McLennan | Non Exec Director | 31/07/2017 | 01/02/2019 |
| James Allchurch | Managing Director, CEO | 09/12/2009 | 01/09/2016 |
| Gary Steinepreis | Director | 26/06/2009 | 12/01/2016 |
| Patrick Burke | Director | 26/06/2009 | 12/01/2016 |
Date of first appointment, title may have changed.
Contact Us | Financial Services Guide | Privacy Policy
This website is owned and operated by Investogain Pty Limited.
ABN 88 129 443 447 | AFSL 334036
Information provided is of a general nature and not for trading or advice.
Copyright © 2002-2025 Investogain Pty Limited. All rights reserved.
